Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (121-130 of 274) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|January 12, 2008
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separationChristopher M Mahaffey, Angela M Davies, Primo N Lara, et al.
Clinical Lung Cancer|January 1, 2017
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung CancerMatthew S Lara, William S Holland, Danielle Chinn, et al.
Cancer|September 5, 2002
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?Regina Gandour-Edwards, Primo N Lara, Ann K Folkins, et al.
Cancer|August 26, 2010
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124Primo N Lara, Kari Chansky, Taro Shibata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancerGlenn Liu, David R Gandara, Primo N Lara, et al.
Clinical Lung Cancer|February 2, 2025
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database AnalysisMatthew S Lara, Jonathan W Riess, Guneet Kaleka, et al.
British Journal of Haematology|September 22, 2016
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium StudyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
International Journal of Clinical Oncology|March 25, 2011
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinomaDerek Shek, Jeff Longmate, David I Quinn, et al.
Clinical Lung Cancer|February 18, 2004
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trialPrimo N Lara, Luko Laptalo, Jeff Longmate, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111Maha Hussain, Catherine M Tangen, Primo N Lara, et al.
Pageof 28

Showing results (121-130 of 274) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|January 12, 2008
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separationChristopher M Mahaffey, Angela M Davies, Primo N Lara, et al.
Clinical Lung Cancer|January 1, 2017
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung CancerMatthew S Lara, William S Holland, Danielle Chinn, et al.
Cancer|September 5, 2002
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?Regina Gandour-Edwards, Primo N Lara, Ann K Folkins, et al.
Cancer|August 26, 2010
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124Primo N Lara, Kari Chansky, Taro Shibata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancerGlenn Liu, David R Gandara, Primo N Lara, et al.
Clinical Lung Cancer|February 2, 2025
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database AnalysisMatthew S Lara, Jonathan W Riess, Guneet Kaleka, et al.
British Journal of Haematology|September 22, 2016
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium StudyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
International Journal of Clinical Oncology|March 25, 2011
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinomaDerek Shek, Jeff Longmate, David I Quinn, et al.
Clinical Lung Cancer|February 18, 2004
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trialPrimo N Lara, Luko Laptalo, Jeff Longmate, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111Maha Hussain, Catherine M Tangen, Primo N Lara, et al.
Pageof 28